443 | a Phase 1 Study of Prt2527, a Selective Cdk9 Inhibitor, as Monotherapy and in Combination with Zanubrutinib in Relapsed/refractory Lymphoid Malignancies: Updated Analysis
No Thumbnail Available
All Authors
Jurczak,W.
Sarkozy,C.
Lewis,K. L.
Shouse,G.
Hawkes,E. A.
Kim,W. S.
Tani,M.
Lemonnier,F.
Assouline,S. E.
Morschhauser,F.
LTHT Author
Munir, Talha
LTHT Department
Oncology
Haematology
Haematology
Non Medic
Publication Date
2025
Item Type
Article
Language
Subject
Subject Headings
Abstract
Journal
Hematological oncology